NightHawk Biosciences Inc (NHWK)

[itsabouttime]

Could think of several International Pharma companies interested financing this science.


Shattuck Labs, Inc.



What We Do (non-layperson’s version)

The technology being developed at Shattuck Labs was conceived in order to address two basic flaws in current cancer immunotherapeutics. The first (which is partially solved by technologies including bispecific antibodies, BiTEs, DARTs and engineered scFv’s) is to design biologic molecules that are endowed with multiple functionalities. The second (not solved by any of the technologies mentioned above) is to design a biologic molecule that can simultaneously block candidate checkpoint molecules in cancer while also stimulating TNF superfamily costimulatory receptors on T cells (and innate cells). The technology platform is called ARC (Agonist Redirected Checkpoints), and is adaptable to most of the checkpoint targets currently in clinical development. We are currently entering cell line development for several lead molecules, and expect to be in the clinic within the next 18 months.